Cochrane Review Finds Anti-Amyloid Alzheimer's Drugs Ineffective and Risky
A recent review by the Cochrane Collaboration has concluded that anti-amyloid drugs, which target amyloid beta proteins in the brain, do not provide clinically meaningful benefits for patients with Alzheimer's disease. The review analyzed data from 17 clinical trials involving 20,342 participants with mild cognitive impairment or mild dementia due to Alzheimer's. Despite the removal of amyloid proteins from the brain, these drugs did not significantly impact cognitive decline or dementia severity. Furthermore, the review highlighted an increased risk of brain swelling and bleeding associated with these drugs, although most patients did not exhibit symptoms. The findings suggest that while these drugs can remove amyloid proteins, this does not translate into a meaningful clinical benefit for patients. 
